Skip to content
Opening soonHORIZON-MISS-2027-02-CANCER-01HaDEAOne-off

Leveraging functional genomics to reveal novel targets for cancer treatment

Research using functional genomics into new targets for cancer treatment.

Research and innovation action under the EU Mission on Cancer for consortia that use functional genomics and multi-omics to identify and validate new therapeutic targets for cancer, with attention to paediatric and rare cancers.

Opening soon
84
days until opening
Opens on 10 February 2027
HORIZON-MISS-2027-02-CANCER-01
View all deadlines
Beta

This grant database is in beta

Until the official launch on 1 January 2027 we are making the final improvements. Our editors check every scheme, but details may still be incomplete or out of date. Check the official publication before you apply.

In brief

What is Leveraging functional genomics to reveal novel targets for cancer treatment?

Who
A consortium of at least three independent organisations from three different EU Member States or Associated Countries, at least one of which is from a Member State. Companies of any size, research organisations, public authorities, foundations and associations can participate.
General Annex B (Entities eligible to participate; Entities eligible for funding; Consortium composition)
What for
A research and innovation action that uses functional genomics to improve understanding of cancer onset and progression, in order to find more precise and new therapeutic targets.
Topic HORIZON-MISS-2027-02-CANCER-01 (Expected Outcome; Scope)
What you get
A grant covering 100% of eligible costs; the Commission considers an EU contribution of €7 to €8 million per project appropriate. The indicative budget for the topic is just over €32.3 million, with 4 projects expected to be funded.
Topic HORIZON-MISS-2027-02-CANCER-01 (Expected EU contribution per project; Indicative budget); General Annex G, Funding rates
What you need to do
Submit a proposal in a single stage via the Funding & Tenders Portal from 10 February 2027 until 16 September 2027 at the latest (17:00 Brussels time), with application form Part A and Part B and, if the proposal includes clinical studies, an annex on those studies. Independent experts evaluate and rank the proposals; results are expected around 5 months after the deadline.
Call HORIZON-MISS-2027-02 overview (Opening; Deadline); topic Scope; General Annexes E and F

Built from the details on this page, with nothing added by us.

Purpose & impact

Why does this scheme exist?

To improve understanding of cancer onset and progression in order to find more precise and new therapeutic targets.

01
Insight into tumour heterogeneity
Researchers and healthcare professionals better understand the functional effects of tumour heterogeneity in cancer onset and progression, which helps to find new and more precise therapeutic targets.
02
Knowledge and tools for new treatments
Researchers, healthcare professionals and innovators have better knowledge and tools for developing a new generation of genomics-based cancer treatments.
03
Contribution to the UNCAN.eu data platform
Researchers and professionals contribute to the UNCAN.eu research data platform through interoperable data and sustainable access to new digital tools and models for multimodal clinical data.
Description

About the scheme

Compiled from passages of the scheme's official publication, with nothing added by us.

Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: - Researchers and health professionals gain a deeper understanding of the functional effects of tumour heterogeneity during cancer initiation and progression, supporting the identification of more precise and novel therapeutic targets. - Researchers, health professionals and innovators benefit from improved knowledge and tools to support the discovery and development of next generation genomically-informed cancer treatments. - Researchers, innovators, and professionals across disciplines and sectors contribute to the UNCAN.eu research data platform by ensuring data interoperability, and enabling sustainable access to newly developed digital tools and models for the analysis and management of multimodal clinical data.

Am I eligible?

Conditions

Quoted verbatim from the scheme, with the article that sets each condition.

01
To be eligible for funding, applicants must be established in one of the following countries: – the Member States of the European Union, including their outermost regions: … – countries associated to Horizon Europe
02
Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.
03
Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.
04
Subject to restrictions for the protection of European communication networks.
All sizes
Micro< 10 FTE
Small< 50 FTE
Medium< 250 FTE
Large≥ 250 FTE
Themes
Wetenschappelijk onderzoekOnderzoek, ontwikkeling en innovatieZiekenhuiszorg en medische zorgGezondheid, zorg en welzijn
Project phase
ResearchDevelopment
Funding

What do you get?

100% of your eligible project costs.

Note on the maximum
Indicatively between EUR 7 and 8 million per project; other amounts are not excluded.
Total scheme budget
€32.3m · Indicative topic budget, 4 projects expected to be funded.
Budget status
Not published by the source
The sources do not say how much budget is left (checked 18 November 2026).
No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants) and the same costs may never be declared under two different EU actions (General Annex G).
Type
Direct grant (non-repayable)
Calendar

Deadlines & cycles

10
FEB
HORIZON-MISS-2027-02-CANCER-01 opens 10 February 2027
Call HORIZON-MISS-2027-02, overview of this call
Cycle: Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F). General Annex F, Indicative timetable for evaluation and for signature of the grant agreement
Application

How do you apply?

Pre-registration
Required, before the full application
Required attachments
  • Application form Part A: administrative information on the participants and summarised budget (to be completed online)
  • Application form Part B: technical description of the project (PDF, maximum 40 pages)
  • Annex with information on clinical studies (HE template), if the proposal includes clinical studies
Procedure
Apply via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).
Eligible costs

What can the money be spent on?

Personnel costs
Materials
Not eligible
Subcontracting
Equipment
Land
Not eligible
Buildings
Not eligible
Overheads
Travel costs
Other costs
Actual costs: personnel, subcontracting, travel, equipment, other goods and services, plus 25% indirect costs.
Downloads

Files & forms

Changes

What has changed?

10 November 2026scheme · version 5

Subtitle
Subtitle: ChangedShow
Before

Onderzoek met functionele genomica naar nieuwe aangrijpingspunten voor kankerbehandeling.

Now

Research using functional genomics into new targets for cancer treatment.

Description
Description: ChangedShow
Before

Projecten ontwikkelen experimentele modellen en technologieën om de functionele effecten van tumorheterogeniteit op ontstaan, progressie en terugkeer van kanker te onderzoeken, bestuderen mechanismen van therapieresistentie en integreren FAIR multimodale longitudinale patiëntdata. Data en tools komen beschikbaar via het UNCAN.eu-platform; samenwerking met UNCAN-CONNECT en deelname aan het cluster 'Understanding'.

Now

Projects develop experimental models and technologies to investigate the functional effects of tumour heterogeneity on cancer onset, progression and recurrence, study mechanisms of therapy resistance and integrate FAIR multimodal longitudinal patient data. Data and tools are made available via the UNCAN.eu platform; collaboration with UNCAN-CONNECT and participation in the 'Understanding' cluster.

Short description
Short description: ChangedShow
Before

Onderzoeks- en innovatieactie van de EU-kankermissie voor consortia die met functionele genomica en multi-omics nieuwe therapeutische doelwitten voor kanker identificeren en valideren, met aandacht voor kinder- en zeldzame kankers.

Now

Research and innovation action under the EU Mission on Cancer for consortia that use functional genomics and multi-omics to identify and validate new therapeutic targets for cancer, with attention to paediatric and rare cancers.

Cycle
Cycle: ChangedShow
Before

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Now

Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F).

Note on the total budget
Note on the total budget: ChangedShow
Before

Indicatief topicbudget, naar verwachting 4 projecten.

Now

Indicative topic budget, 4 projects expected to be funded.

Note on the maximum
Note on the maximum: ChangedShow
Before

Indicatief tussen EUR 7 en 8 miljoen per project; andere bedragen zijn niet uitgesloten.

Now

Indicatively between EUR 7 and 8 million per project; other amounts are not excluded.

Cumulation
Cumulation: ChangedShow
Before

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Now

No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants) and the same costs may never be declared under two different EU actions (General Annex G).

Search engine title
Kankermissie: functionele genomica voor nieuwe targets becomes Cancer Mission: functional genomics for new targets
Search engine description
Search engine description: ChangedShow
Before

Horizon Europe kankermissie: onderzoek met functionele genomica en multi-omics naar nieuwe doelwitten voor kankerbehandeling.

Now

Horizon Europe Cancer Mission: research using functional genomics and multi-omics into new targets for cancer treatment.

Keywords
EU-missie Cancer, functionele genomica, Horizon Europe, HORIZON-MISS-2027-02-CANCER-01, nieuwe kankerbehandelingen, tumorheterogeniteit becomes EU Mission Cancer, functional genomics, Horizon Europe, HORIZON-MISS-2027-02-CANCER-01, new cancer treatments, tumour heterogeneity
Language
Dutch (Netherlands) becomes British English
Required attachments
Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 40 pagina's); Bijlage met informatie over klinische studies (HE-sjabloon), als het voorstel klinische studies omvat becomes Application form Part A: administrative information on the participants and summarised budget (to be completed online); Application form Part B: technical description of the project (PDF, maximum 40 pages); Annex with information on clinical studies (HE template), if the proposal includes clinical studies
Procedure
Procedure: ChangedShow
Before

Aanvragen via het Funding & Tenders Portal met een EU Login en een PIC-nummer; single-stage; deadline 17:00 uur Brusselse tijd; beheerd door European Health and Digital Executive Agency (HaDEA).

Now

Apply via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).

Notes per cost type
Notes per cost type: ChangedShow
Before

Other costs: Werkelijke kosten: personeel, onderaannemers, reizen, apparatuur, overige goederen en diensten, plus 25% indirecte kosten.

Now

Other costs: Actual costs: personnel, subcontracting, travel, equipment, other goods and services, plus 25% indirect costs.

Why this scheme
Why this scheme: ChangedShow
Before

Het begrip van het ontstaan en de progressie van kanker vergroten om preciezere en nieuwe therapeutische doelwitten te vinden.

Now

To improve understanding of cancer onset and progression in order to find more precise and new therapeutic targets.

In brief
In brief: ChangedShow
Before

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minstens één uit een lidstaat. Bedrijven van elke omvang, onderzoeksinstellingen, overheden, stichtingen en verenigingen kunnen deelnemen.

What for: Een onderzoeks- en innovatieactie die met functionele genomica het begrip van het ontstaan en de progressie van kanker vergroot, om preciezere en nieuwe therapeutische doelwitten te vinden.

What you get: Een subsidie van 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 7 tot € 8 miljoen per project passend. Het indicatieve budget voor het topic is ruim € 32,3 miljoen, naar verwachting voor 4 projecten.

What you need to do: Dien van 10 februari 2027 tot uiterlijk 16 september 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A en B en, als het voorstel klinische studies omvat, een bijlage over die studies. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt naar verwachting circa 5 maanden na de deadline.

Now

Who: A consortium of at least three independent organisations from three different EU Member States or Associated Countries, at least one of which is from a Member State. Companies of any size, research organisations, public authorities, foundations and associations can participate.

What for: A research and innovation action that uses functional genomics to improve understanding of cancer onset and progression, in order to find more precise and new therapeutic targets.

What you get: A grant covering 100% of eligible costs; the Commission considers an EU contribution of €7 to €8 million per project appropriate. The indicative budget for the topic is just over €32.3 million, with 4 projects expected to be funded.

What you need to do: Submit a proposal in a single stage via the Funding & Tenders Portal from 10 February 2027 until 16 September 2027 at the latest (17:00 Brussels time), with application form Part A and Part B and, if the proposal includes clinical studies, an annex on those studies. Independent experts evaluate and rank the proposals; results are expected around 5 months after the deadline.

Goals
Goals: 3 removed, 3 newShow
Removed

Inzicht in tumorheterogeniteit Onderzoekers en zorgprofessionals begrijpen de functionele effecten van tumorheterogeniteit bij het ontstaan en de progressie van kanker beter, wat helpt nieuwe en preciezere therapeutische targets te vinden.

Kennis en instrumenten voor nieuwe behandelingen Onderzoekers, zorgprofessionals en innovatoren beschikken over betere kennis en instrumenten voor de ontwikkeling van een nieuwe generatie genomisch onderbouwde kankerbehandelingen.

Bijdrage aan het UNCAN.eu-dataplatform Onderzoekers en professionals dragen bij aan het UNCAN.eu-onderzoeksdataplatform door interoperabele data en duurzame toegang tot nieuwe digitale instrumenten en modellen voor multimodale klinische data.

New

Insight into tumour heterogeneity Researchers and healthcare professionals better understand the functional effects of tumour heterogeneity in cancer onset and progression, which helps to find new and more precise therapeutic targets.

Knowledge and tools for new treatments Researchers, healthcare professionals and innovators have better knowledge and tools for developing a new generation of genomics-based cancer treatments.

Contribution to the UNCAN.eu data platform Researchers and professionals contribute to the UNCAN.eu research data platform through interoperable data and sustainable access to new digital tools and models for multimodal clinical data.

Show 4 earlier versions

20 October 2026scheme · version 4

Conditions
Conditions: 6 removed, 4 newShow
Removed

Consortium van minimaal drie partners Ten minste drie onafhankelijke rechtspersonen uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minstens één uit een lidstaat.

Voorrang voor kinder- en jeugdkanker Ten minste één hoogst gerangschikt voorstel gericht op kinderen en adolescenten (0-19 jaar bij diagnose) wordt gefinancierd, mits het alle drempels haalt.

Data via UNCAN.eu Digitale middelen worden beschikbaar gesteld via het UNCAN.eu-platform, datasets worden beschreven in de EU-datasetcatalogus van de European Health Data Space en er wordt samengewerkt met UNCAN-CONNECT.

Deelname aan projectcluster Gehonoreerde projecten nemen deel aan het cluster 'Understanding' van de kankermissie en begroten voor netwerken, bijeenkomsten en gezamenlijke activiteiten.

Klinische studies Voorstellen met klinische studies leveren details aan in de daarvoor bestemde bijlage.

Hogere drempels bij beoordeling Drempel 4 per criterium (excellentie, impact, uitvoering) en cumulatief 12.

New

To be eligible for funding, applicants must be established in one of the following countries: – the Member States of the European Union, including their outermost regions: … – countries associated to Horizon Europe

Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.

Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.

Subject to restrictions for the protection of European communication networks.

In brief
In brief: AddedShow
Now

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minstens één uit een lidstaat. Bedrijven van elke omvang, onderzoeksinstellingen, overheden, stichtingen en verenigingen kunnen deelnemen.

What for: Een onderzoeks- en innovatieactie die met functionele genomica het begrip van het ontstaan en de progressie van kanker vergroot, om preciezere en nieuwe therapeutische doelwitten te vinden.

What you get: Een subsidie van 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 7 tot € 8 miljoen per project passend. Het indicatieve budget voor het topic is ruim € 32,3 miljoen, naar verwachting voor 4 projecten.

What you need to do: Dien van 10 februari 2027 tot uiterlijk 16 september 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A en B en, als het voorstel klinische studies omvat, een bijlage over die studies. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt naar verwachting circa 5 maanden na de deadline.

18 October 2026scheme · version 3

About the scheme
About the scheme: AddedShow
Now

Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: - Researchers and health professionals gain a deeper understanding of the functional effects of tumour heterogeneity during cancer initiation and progression, supporting the identification of more precise and novel therapeutic targets. - Researchers, health professionals and innovators benefit from improved knowledge and tools to support the discovery and development of next generation genomically-informed cancer treatments. - Researchers, innovators, and professionals across disciplines and sectors contribute to the UNCAN.eu research data platform by ensuring data interoperability, and enabling sustainable access to newly developed digital tools and models for the analysis and management of multimodal clinical data.

16 October 2026scheme · version 2

Cycle
Cycle: AddedShow
Now

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Cumulation
Cumulation: AddedShow
Now

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Keywords
Added: EU-missie Cancer, functionele genomica, Horizon Europe, HORIZON-MISS-2027-02-CANCER-01, nieuwe kankerbehandelingen, tumorheterogeniteit
Required attachments
Added: Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 40 pagina's); Bijlage met informatie over klinische studies (HE-sjabloon), als het voorstel klinische studies omvat
Goals
Goals: 3 newShow
New

Inzicht in tumorheterogeniteit Onderzoekers en zorgprofessionals begrijpen de functionele effecten van tumorheterogeniteit bij het ontstaan en de progressie van kanker beter, wat helpt nieuwe en preciezere therapeutische targets te vinden.

Kennis en instrumenten voor nieuwe behandelingen Onderzoekers, zorgprofessionals en innovatoren beschikken over betere kennis en instrumenten voor de ontwikkeling van een nieuwe generatie genomisch onderbouwde kankerbehandelingen.

Bijdrage aan het UNCAN.eu-dataplatform Onderzoekers en professionals dragen bij aan het UNCAN.eu-onderzoeksdataplatform door interoperabele data en duurzame toegang tot nieuwe digitale instrumenten en modellen voor multimodale klinische data.

7 October 2026scheme · version 1 · first publication

Source

Contact & source

Funding body
European Health and Digital Executive Agency
Last verified
17 November 2026 by the Twin editors
Start your application

Start your HORIZON-MISS-2027-02-CANCER-01 application
in Twin.

Twin helps you write your application, based on the scheme and your own project documents. You stay in control of every text.